Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Articles published by Rayzebio, Inc.
Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
December 26, 2023
From
Rayzebio, Inc.
Via
GlobeNewswire
Tickers
BMY
RYZB
RayzeBio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 13, 2023
From
Rayzebio, Inc.
Via
GlobeNewswire
Tickers
RYZB
RayzeBio to Participate in Upcoming Investor Conferences in November 2023
November 06, 2023
From
Rayzebio, Inc.
Via
GlobeNewswire
Tickers
RYZB
RayzeBio Appoints Industry Leader Tim Van Hauwermeiren to Its Board of Directors
November 01, 2023
From
Rayzebio, Inc.
Via
GlobeNewswire
Tickers
RYZB
FDA selects RayzeBio to Participate in the Inaugural CDRP Program to Expedite Commercial Manufacturing Readiness for RYZ101 in GEP-NETs
October 24, 2023
From
Rayzebio, Inc.
Via
GlobeNewswire
Tickers
RYZB
RayzeBio to Present at European Society for Medical Oncology (ESMO) Congress
October 18, 2023
From
Rayzebio, Inc.
Via
GlobeNewswire
Tickers
RYZB
RayzeBio, Inc. Announces Closing of Upsized $358 Million Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
September 19, 2023
From
RayzeBio, Inc.
Via
Business Wire
Tickers
RYZB
RayzeBio, Inc. Announces Pricing of Upsized $311 Million Initial Public Offering
September 14, 2023
From
RayzeBio, Inc.
Via
Business Wire
RayzeBio Appoints Christy Oliger to its Board of Directors
August 29, 2023
From
RayzeBio, Inc.
Via
Business Wire
RayzeBio to Present at Society of Nuclear Medicine and Molecular Imaging Annual Meeting
June 22, 2023
From
RayzeBio, Inc.
Via
Business Wire
RayzeBio Announces First Patient Dosed in Phase 3 ACTION-1 Study, Evaluating RYZ101 (Actinium-225 DOTATATE) in Neuroendocrine Tumors
May 31, 2023
From
RayzeBio, Inc.
Via
Business Wire
RayzeBio to Present at Upcoming Medical Conferences
May 22, 2023
From
RayzeBio, Inc.
Via
Business Wire
RayzeBio Nominates Glypican-3 (GPC3) Targeted Radiopharmaceutical Therapy Drug Candidate for Treatment of Liver Cancer
March 21, 2023
From
RayzeBio, Inc.
Via
Business Wire
RayzeBio Completes Phase 1b Enrollment in ACTION-1 Study, Evaluating RYZ101 (Actinium-225 DOTATATE) in Neuroendocrine Tumors
March 20, 2023
From
RayzeBio, Inc.
Via
Business Wire
RayzeBio Announces Issuance of Two Patents for RYZ101 (225Ac-DOTATATE)
January 04, 2023
From
RayzeBio, Inc.
Via
Business Wire
RayzeBio to Present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023
January 04, 2023
From
RayzeBio, Inc.
Via
Business Wire
RayzeBio Appoints Industry Veteran Rich Heyman, Ph.D. as Chairman of Board of Directors
December 07, 2022
From
RayzeBio, Inc.
Via
Business Wire
RayzeBio to Present at Upcoming Investor Conferences in November 2022
November 14, 2022
From
RayzeBio, Inc.
Via
Business Wire
RayzeBio Propels Forward with $418 Million Raised Since Inception to Advance Targeted Radiopharmaceuticals for Cancer
September 13, 2022
From
RayzeBio, Inc.
Via
Business Wire
RayzeBio Advances RYZ101, a Targeted Radiopharmaceutical Delivering Actinium-225, into Clinical Development for Two Cancer Indications
September 13, 2022
From
RayzeBio, Inc.
Via
Business Wire
RayzeBio Appoints Angie You, Ph.D., to its Board of Directors
April 25, 2022
From
RayzeBio, Inc.
Via
Business Wire
RayzeBio Expands Leadership Team with Arvind Kush as Chief Financial Officer; and Aubrey Haddach, J.D., as General Counsel
January 24, 2022
From
RayzeBio, Inc.
Via
Business Wire
RayzeBio to Present at J.P. Morgan Healthcare Virtual Conference on Tuesday, January 11, 2022
January 06, 2022
From
RayzeBio, Inc.
Via
Business Wire
RayzeBio Appoints Mary Tagliaferri, M.D. to its Board of Directors and Expands Leadership Team with Rozalyn Littler as VP of Regulatory and Quality
October 12, 2021
From
RayzeBio, Inc.
Via
Business Wire
RayzeBio Expands Leadership Team With Susan Moran, M.D., as Chief Medical Officer; Kimberly Ma, M.S., as SVP of Clinical Operations; and Nicholas Smith, Ph.D., as SVP of Chemistry Innovation
August 31, 2021
From
RayzeBio, Inc.
Via
Business Wire
RayzeBio Secures $108 Million Series C Financing to Drive Forward Its Pipeline of Targeted Radiopharmaceuticals for Cancer
June 15, 2021
From
RayzeBio, Inc.
Via
Business Wire
RayzeBio Appoints Yi Larson to Its Board of Directors and Expands Team with Key Leadership Hires
April 21, 2021
From
RayzeBio, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.